Search

Your search keyword '"Kuck, K. -H."' showing total 744 results
Start Over Author "Kuck, K. -H."
744 results on '"Kuck, K. -H."'

7. Gender matters. Impact of gender on the utilization of defibrillators with cardiac resynchronisation therapy and outcome: results from the German DEVICE registry

Author

Popescu, S S, primary, Gasperetti, A, additional, Brachmann, J, additional, Eckardt, L, additional, Kuck, K H, additional, Willems, S, additional, Lugenbiel, P, additional, Akin, I, additional, Meyer, C, additional, Schneider, S, additional, Hochadel, M, additional, Senges, J, additional, and Tilz, R R, additional

Published
2024
Full Text
View/download PDF

9. In-hospital mortality following catheter ablation procedures in Germany: insights from the VARY project

Author

Tilz, R R, primary, Vogler, J, additional, Sommer, P, additional, Steven, D, additional, Meyer, C, additional, Pauschinger, M, additional, Kuniss, M, additional, Doll, N, additional, Zahn, R, additional, Voigtlaender, T, additional, Kuck, K H, additional, Schneider, S, additional, Senges, J, additional, Brachmann, J, additional, and Lewalter, T, additional

Published
2024
Full Text
View/download PDF

22. Comparison of quality-of-life following cryoballoon versus radiofrequency catheter ablation of symptomatic atrial fibrillation - a subanalysis of the FREEZE cohort study

Author

Straube, F, primary, Dorwarth, U, additional, Pongratz, J, additional, Riess, L, additional, Kuniss, M, additional, Tebbenjohanns, J, additional, Noelker, G, additional, Tilz, R, additional, Chun, J, additional, Stellbrink, C, additional, Metzner, A, additional, Brachmann, J, additional, Kuck, K H, additional, Senges, J, additional, and Hoffmann, E, additional

Published
2023
Full Text
View/download PDF

24. An international two-centre experience with the third generation laser balloon system: safety, efficiency, and efficacy

Author

Martignani, C, primary, Bartoli, L, additional, Spadotto, A, additional, Massaro, G, additional, Piemontese, G P, additional, Angeletti, A, additional, Ziacchi, M, additional, Phan, H L, additional, Keelani, A, additional, Eitel, C, additional, Vogler, J, additional, Biffi, M, additional, Kuck, K H, additional, Tilz, R R, additional, and Heeger, C H, additional

Published
2023
Full Text
View/download PDF

45. Presenting Pattern of Atrial Fibrillation and Outcomes of Early Rhythm Control Therapy

Author

Goette, A, Borof, K, Breithardt, G, Camm, AJ, Crijns, HJGM, Kuck, K-H, Wegscheider, K, Kirchhof, P, and EAST-AFNET 4 Investigators

Abstract

BACKGROUND: Whether atrial fibrillation (AF) pattern or timing of AF therapy modifies the effectiveness of early rhythm control (ERC) is not known. OBJECTIVES: This study sought to compare clinical characteristics and outcomes in patients presenting with different AF patterns on ERC vs usual care. METHODS: The effects of ERC were compared in first-diagnosed AF (FDAF), paroxysmal AF (paroxAF), and persistent AF (persAF) in this prespecified analysis of the EAST-AFNET 4 (Early treatment of atrial fibrillation for stroke prevention) trial. Associations between AF pattern and primary outcomes (first primary outcome: cardiovascular death, stroke, and hospitalization for heart failure and acute coronary syndrome; second primary outcome: nights spent in hospital per year) were compared over a mean follow-up of 5.1 years. Changes in health-related quality of life were assessed by the EQ-5D. RESULTS: FDAF patients (n = 1,048, enrolled 7 days after diagnosing AF) were slightly older (71 years of age, 48.0% female) than patients with paroxAF (n = 994, 70 years of age, 50.0% female) and persAF (n = 743, 70 years of age, 38.0% female). ERC reduced the primary outcome in all 3 AF patterns. Hospitalizations for acute coronary syndrome were highest in FDAF (incidence rate ratio [IRR]: 1.50; 95% CI: 0.83-2.69; P for interaction = 0.032) compared with paroxAF (IRR: 0.64; 95% CI: 0.32-1.25) and persAF (IRR: 0.50; 95% CI: 0.25-1.00). FDAF patients spent more nights in hospital (IRR: 1.38; 95% CI: 1.12-1.70; P for interaction = 0.004) than paroxAF (IRR: 0.84; 95% CI: 0.67-1.03), and persAF (IRR: 1.02; 95% CI: 0.80-1.30) patients. ERC improved health-related quality of life (EQ-5D score) in patients with paroxAF and persAF but not in patients with FDAF (P = 0.019). CONCLUSIONS: ERC reduces the first primary composite outcome in all AF patterns. Patients with FDAF are at high risk for hospitalization and acute coronary syndrome, particularly on ERC. (Early treatment of atrial fibrillation for stroke prevention trial; ISRCTN04708680; Early Treatment of Atrial Fibrillation for Stroke Prevention Trial [EAST]; NCT01288352; Early treatment of Atrial fibrillation for Stroke prevention Trial [EAST]; EudraCT2010-021258-20).

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results